3082412-00-5
Chemical Structure
KRAS-IN-5
- CAS No.: 3082412-00-5
- Formula:C35H36F3N7O3
- Molecular Weight:659.70
InChIKey: XVMXDENYYVXFTQ-RZGOILFOSA-N
SMILES: FC1=C(CC)C2=C(C=C(NN=C3C)C3=C2C4=C(F)C(N=C(OC[C@@]56CCCN5C[C@H](F)C6)N=C7N(CCCOC8)[C@@H]8CO9)=C7C9=N4)C=C1
Biological Activity: KRAS-IN-5 (Compound Ex 6) is an orally active and selective inhibitor targeting KRAS mutants (including KRASG12D, KRASG12V, KRASWT) with a GNE IC50 value of 1.3 nM against KRASG12D. KRAS-IN-5 blocks tumor cell proliferation by inhibiting KRAS-mediated signaling pathways (e.g., reducing ERK phosphorylation). KRAS-IN-5 is promising for research of KRAS mutation-related cancers, such as pancreatic cancer, colorectal cancer, lung cancer[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
KRAS-IN-5 | KRAS-IN-5 (Compound Ex 6) is an orally active and selective inhibitor targeting KRAS mutants (including KRASG12D, KRASG12V, KRASWT) with a GNE IC50 value of 1.3 nM against KRASG12D. KRAS-IN-5 blocks tumor cell proliferation by inhibiting KRAS-mediated signaling pathways (e.g., reducing ERK phosphorylation). KRAS-IN-5 is promising for research of KRAS mutation-related cancers, such as pancreatic cancer, colorectal cancer, lung cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
